MedTrace Logo

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

NCT00796809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 598

Last updated 2015-12-14

No results posted yet for this study

Summary

The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.

Conditions

Sponsors & Collaborators

  • Centocor, Inc.

    collaborator INDUSTRY

  • University of Arizona

    lead OTHER

Principal Investigators

  • Berchman A Vaz, MD, PhD · University of Arizona

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-06-30
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00796809 on ClinicalTrials.gov